ストックスクリーナーアプリを入手
0.5246
6.02%
-0.0336
プレマーケット:
.53
0.0054
+1.03%
前日終値:
$0.5582
開ける：
$0.58
24時間の取引高:
354.91K
Relative Volume:
0.98
時価総額：
$11.19M
収益：
$1.44M
当期純損益:
$-21.34M
株価収益率:
-0.3923
EPS:
-1.3371
ネットキャッシュフロー:
$-17.38M
1週間 パフォーマンス:
-4.37%
1か月 パフォーマンス:
-2.82%
6か月 パフォーマンス:
-29.88%
1年 パフォーマンス:
-60.56%
1日の値動き範囲:
$0.5201
$0.58
1週間の範囲:
$0.50
$0.5923
52週間の値動き範囲:
$0.492
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5246 | 11.91M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
Longeveron Inc (LGVN) 最新ニュース
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan
LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LGVN: Trial Results Encouraging - Research Tree
LGVN Should I Buy - Intellectia AI
Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI
Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com
Longeveron publishes phase 2b stem cell trial results in journal - Investing.com
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron publishes phase 2b stem cell trial results in journal By Investing.com - Investing.com South Africa
Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times
Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru
LGVN: New CEO and Fresh Cost Reductions - Research Tree
Longeveron Appoints Stephen Willard as CEO - citybiz
Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Longeveron Appoints New CEO to Lead Pivotal Clinical Trials - National Today
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail
Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results - Investing.com Australia
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results By Investing.com - Investing.com South Africa
Longeveron Appoints New CEO to Drive Growth - Intellectia AI
Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell - Quiver Quantitative
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - The Manila Times
New Longeveron CEO steps in as pivotal stem cell trial nears - Stock Titan
Gains Recap: Is Longeveron Inc. stock supported by strong fundamentalsEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru
Is Longeveron Inc. exposed to currency risksQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Is Longeveron Inc. still a buy after recent gains2025 Earnings Surprises & Consistent Return Investment Signals - mfd.ru
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times
Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan
Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa
Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria
Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn
Published on: 2026-01-27 00:29:51 - baoquankhu1.vn
Longeveron Granted FDA Type C Meeting Ahead Of Pivotal ELPIS II Data For HLHS - Nasdaq
Longeveron Inc (LGVN) 財務データ
収益
当期純利益
現金流量
EPS
Longeveron Inc (LGVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):